Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988122 | 0.87 | TAAR1 (0.54) | TAAR1SLC6A3DAOCYP4F2CYP4A11 | |
| SCHEMBL81108 | 0.87 | TAAR1 (0.59) | TAAR1SLC6A3IDO1AGXTDAO | |
| SCHEMBL3371633 | 0.85 | TAAR1 (0.74) | TAAR1SLC6A3IDO1AGXTDAO | |
| SCHEMBL1043921 | 0.85 | TAAR1 (0.57) | TAAR1SLC6A3IDO1AGXTDAO | |
| SCHEMBL1047220 | 0.84 | TAAR1 (0.55) | TAAR1SLC6A3DRD2SLC6A4CYP4F2 | |
| SCHEMBL2955082 | 0.84 | TAAR1 (0.55) | TAAR1SLC6A3DRD2SLC6A4CYP4F2 | |
| SCHEMBL239199 | 0.83 | TDP1 (0.65) | TAAR1TDP1DRD2CYP4F2CYP4A11 | |
| SCHEMBL38187 | 0.81 | — | — | |
| SCHEMBL30583036 | 0.81 | — | — | |
| SCHEMBL15736377 | 0.81 | TAAR1 (0.57) | TAAR1SLC6A3IDO1AGXTDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 462 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020064917-A1 | PRODUCTION OF AMINES VIA A HYDROAMINOMETHYLATION REACTION USING IMINIUM REACTANTS | Universität Wien (AT) | 2020-04-02 | — | — | WO | claimed |
| EP-3628657-A1 | PRODUCTION OF AMINES VIA A HYDROAMINOMETHYLATION REACTION USING IMINIUM REACTANTS | Universität Wien (AT) | 2020-04-01 | — | — | EP | claimed |
| WO-2015172747-A1 | SPIROCYCLIC MOLECULES AS MTH1 INHIBITORS | WANG ZHAOYIN (CN) | 2015-11-19 | — | — | WO | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2025-03-27 | — | — | US | disclosed |
| CN-119528906-A | Azaspiro compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025014719-A2 | TROPANE COMPOUNDS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-0251775-B1 | ALPHA-ARYL-ALPHA-PHENYLETHYL-1H-1,2,4-TRIAZOLE-1-PROPANENITRILES | ROHM AND HAAS COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| CN-1068118-A | Imidazo [2, 1-b ] [3] benzazepine derivatives, compositions and methods of use | JANSSEN PHARMACEUTICA NV (BE) | 1993-01-20 | — | — | CN | disclosed |
| WO-1992022551-A1 | IMIDAZO[2,1-b][3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518435-A1 | Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
| EP-0496342-A1 | New hydrazine derivative and pesticidal composition comprising said derivative as an effective ingredient | Nippon Kayaku Kabushiki Kaisha (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-5087635-A | Funcicides | ROHM AND HAAS COMPANY (US) | 1992-02-11 | — | — | US | disclosed |
| EP-0380312-A1 | Pesticidal compounds | ROUSSEL-UCLAF (FR) | 1990-08-01 | — | — | EP | disclosed |
| EP-0251775-A2 | Alpha-aryl-alpha-phenylethyl-1H-1,2,4-triazole-1-propanenitriles | ROHM AND HAAS COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101012-A1 | HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS | ERG28, DPM1, CYP51A1 | TAAR1 3783/4885TDP1 3324/4885SLC6A3 4336/4885 |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | TAAR1 893/4885TDP1 863/4885SLC6A3 89/4885 |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | TAAR1 97/4885TDP1 387/4885SLC6A3 43/4885 |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | TAAR1 2815/4885TDP1 2489/4885SLC6A3 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.